Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
Biogen Earnings, Revenue Beat in Q4 By Investing.com
12:09pm, Thursday, 03'rd Feb 2022 Investing.com
Biogen Earnings, Revenue Beat in Q4
Biogen Non-GAAP EPS of $3.39 beats by $0.02, revenue of $2.74B beats by $120M
12:00pm, Thursday, 03'rd Feb 2022 Seeking Alpha
Biogen press release (BIIB): Q4 Non-GAAP EPS of $3.39 beats by $0.02.Revenue of $2.74B (-3.9% Y/Y) beats by $120M.FY22 Outlook: Revenue of $9.7B-$10B vs
Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus
10:58am, Thursday, 03'rd Feb 2022
Biogen Inc BIIB posted Q4 sales of 2.73 billion, beating the consensus of $2.62 billion, down 4.2% Y/Y. Thousands of new traders are learning the ins and outs on how to find profitable trades every
Biogen Stock Hits 5-Year Low After Weak Forecast
10:36am, Thursday, 03'rd Feb 2022
The shares of Biogen Inc (NASDAQ:BIIB) are down 5% to trade at $213.70 at last check, as the company's bleak 2022 forecast weighs.
Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates
09:59am, Thursday, 03'rd Feb 2022
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 2.11% and 4.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Biogen Shares Are Sliding Today
09:47am, Thursday, 03'rd Feb 2022
Biogen Inc BIIB is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates. Biogen reported quarterly reve
Biogen's stock falls 3.7% on earnings miss, says it brought in $1 million in sales of Alzheimer's drug in the fourth quarter
07:45am, Thursday, 03'rd Feb 2022
Shares of Biogen Inc. BIIB, -1.92% were down 3.7% in premarket trading on Thursday after missing earnings and revenue expectations in the final quarter of 2021. Biogen had earnings of $368.2 million,
Biogen 2022 profit forecast misses estimates on Aduhelm woes
07:42am, Thursday, 03'rd Feb 2022
Biogen Inc on Thursday forecast 2022 adjusted earnings well below analysts' estimates, as it expects minimal sales from its Alzheimer's drug following the U.S. Medicare regulator's move to limit cover
Were Hedge Funds Right About Biogen Inc. (BIIB)?
08:06pm, Wednesday, 02'nd Feb 2022 Insider Monkey
Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
05:31pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
AbbVie's (ABBV) Q4 Earnings Surpass Estimates, Sales Miss
04:40pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
AbbVie (ABBV) beats fourth-quarter 2021 earnings estimates while missing the same for sales. Strong demand for immunology drugs, aesthetics and cosmetics drives sales. Shares up.
Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes?
04:37pm, Wednesday, 02'nd Feb 2022 Seeking Alpha
Biogen (NASDAQ:BIIB) is scheduled to announce Q4 earnings results on Thursday, February 3rd, before market open.The consensus EPS Estimate is $3.38 (-26.2% Y/Y) and the consensus…
Biotech Stock Roundup: GILD Q4 Earnings, REGN, MRNA's Regulatory Updates & More
04:27pm, Wednesday, 02'nd Feb 2022 Zacks Investment Research
Earnings updates from Gilead (GILD) and regulatory updates are among a few key highlights from the biotech sector during the past week.
Drug/Biotech Stocks Earnings on Feb 3: BIIB, LLY & MRK
01:50pm, Wednesday, 02'nd Feb 2022
Let us take a look at three drug/biotech companies, namely, BIIB, LLY and MRK, which are gearing up for their earnings release.
